maryland – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Fri, 22 Dec 2023 18:09:21 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.5 Cannabix Technologies to Participate in Green Lab Held by Montgomery County Police Department (Maryland) https://mjshareholders.com/cannabix-technologies-to-participate-in-green-lab-held-by-montgomery-county-police-department-maryland/ Fri, 22 Dec 2023 18:09:21 +0000 https://cannabisfn.com/?p=2974219

Ryan Allway

December 22nd, 2023

News, Top News, Top Story


VANCOUVER, British Columbia, Dec. 22, 2023 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”), developer of marijuana and alcohol breath testing devices, reports that it will be participating in a “green lab” testing day in Montgomery County, Maryland held by the Montgomery County Police Department. In particular the Company will be supplying its marijuana breathalyzer technology and sending its own representative to facilitate the collection of breath samples alongside law enforcement officers who are testing subjects under the influence of marijuana. The green lab is being held by the Public Safety Training Academy for the Montgomery County Police Department. Various local, regional and out of state representatives are expected to attend the event being held in early January 2024.

The Montgomery County Police Department has held green lab events since 2017, in order to help train police officers about cannabis driving impairment. The green lab aids officers in Advanced Roadside Impaired Driving Enforcement training which helps them learn of the effects of marijuana, and what signs to look for when conducting sobriety tests. Cannabix will be sending its own representative and Breath Collection Units (“BCU”) (See Figure 1) to collect breath samples at various time points pre and post marijuana consumption by subjects. Furthermore, Cannabix will be introducing its technology as a new tool for detection of marijuana in breath to attendees.

In recent months, Cannabix has been using its BCU and Mass Spectrometer Breath Sampler (“MSBS”) to quantify delta-9 THC in human breath samples. Cannabix scientists are using an internal standard to generate a calibration curve for THC quantification in breath samples. Currently, a limit of detection and limit of quantification have been achieved with human subjects in the low picogram range. This allows detection of THC from smoking and edibles up to 4+ hours after consumption.

Cannabix will look to participate in other green labs tests in order to introduce its products to law enforcement stakeholders and collect important data with real world testing conditions.

Figure 1 Cannabix Technologies Inc BCU Hardware

Fig. 1 Cannabix updated Breath Collection Unit (BCU

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a developer of marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories. Cannabix is working to develop delta-9 THC and alcohol screening devices. Delta-9 THC is the psychoactive component of marijuana that causes impairment. Breath testing for delta-9 THC would allow employers and law enforcement to identify recent marijuana use that better aligns with impairment. Cannabix is the developer of contactless breath alcohol detection devices for employers and other settings.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that its development of breathalyzer technologies will provide any benefit to the Company, and no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials. The is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies. There is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
TerrAscend Closes on Acquisition of Top Performing Maryland Dispensary, Peninsula Alternative Health https://mjshareholders.com/terrascend-closes-on-acquisition-of-top-performing-maryland-dispensary-peninsula-alternative-health/ Wed, 28 Jun 2023 16:05:50 +0000 https://cannabisfn.com/?p=2973846

Ryan Allway

June 28th, 2023

News, Top News


US$14M run rate medical dispensary poised to significantly increase sales with the launch of Maryland’s Adult-Use program on July 1st, and expected to be immediately accretive on an EBITDA and cashflow basis

Located in close proximity to Delaware, with no competitors within a 25-mile radius, this dispensary is expected to quickly become one of TerrAscend’s highest performing retail locations nationwide

TORONTO, June 28, 2023 (GLOBE NEWSWIRE) — TerrAscend Corp. (“TerrAscend” or the “Company”) (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced the closing of its previously announced acquisition of Derby 1, LLC (d/b/a “Peninsula Alternative Health”), a medical dispensary in Maryland. This transaction adds a second dispensary to the Company’s Maryland footprint in advance of adult-use sales, which will begin on July 1, 2023. The transaction is expected to be immediately accretive to TerrAscend on an EBITDA and cashflow basis. TerrAscend recently announced entering into a definitive agreement to acquire Hempaid, LLC (d/b/a “Blue Ridge Wellness”), its third medical dispensary in Maryland once closed.

Peninsula Alternative Health is one of the highest performing medical dispensaries in Maryland with a net revenue run rate of approximately US$14 million. Strategically located near the Delaware border in Salisbury, Maryland, this 8,500 square foot dispensary has no direct competitor within a 25-mile radius. TerrAscend expects to achieve significant sales and margin improvement at this location with the launch of adult-use and by offering a complete selection of its high-quality brands including Kind Tree, Gage, Cookies and Wana. With the close of the Transaction, TerrAscend’s retail footprint increases to 35 dispensaries nationwide.

“Adding a second high-performing medical dispensary in Maryland, and soon to be third, is an important step in our strategy to become a market leader in the state,” said Jason Wild, Executive Chairman of TerrAscend. “We expect Peninsula to quickly become one of our highest performing dispensaries nationwide. With less than a week until the launch of adult-use in Maryland, we are focused on signing additional acquisitions and reaching the four-dispensary cap as our northeast business unit will soon be operating in Maryland under the same successful business model we built in New Jersey.”

The Canadian Securities Exchange (“CSE”) has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

About TerrAscend Corp.
TerrAscend is a leading cannabis company with interests across the North American cannabis sector, including vertically integrated operations in Pennsylvania, New Jersey, Maryland, Michigan and California through TerrAscend Growth Corp. and retail operations in Canada. TerrAscend Growth operates The Apothecarium and Gage dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend Growth’s cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns or licenses several synergistic businesses and brands including Gage Cannabis, The Apothecarium, Cookies, Lemonnade, Ilera Healthcare, Kind Tree, Legend, State Flower, and Valhalla Confections. For more information visit www.terrascend.com.

Caution Regarding Cannabis Operations in the United States
Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute, or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve TerrAscend of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against TerrAscend. The enforcement of federal laws in the United States is a significant risk to the business of TerrAscend and any proceedings brought against TerrAscend thereunder may adversely affect TerrAscend’s operations and financial performance.

Forward Looking Information
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and include statements with respect to future revenue and profits. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, the success of the launch of adult use sales in Maryland and in the Peninsula transaction specifically, current and future market conditions; risks related to federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States; and the risk factors set out in the Company’s most recently filed MD&A, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com and in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission on March 16, 2023.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether, as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

For more information regarding TerrAscend:
Keith Stauffer
Chief Financial Officer
717-343-5386
IR@terrascend.com

Briana Chester
MATTIO Communications
424-465-4419
terrascend@mattio.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Maryland and Missouri Have Legalized Recreational Cannabis https://mjshareholders.com/maryland-and-missouri-have-legalized-recreational-cannabis/ Thu, 10 Nov 2022 08:45:51 +0000 https://marijuanastocks.com/?p=55254 Recreational Cannabis Is Now Legal In Missouri and Maryland

The post Maryland and Missouri Have Legalized Recreational Cannabis appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

]]>

<!– (adsbygoogle = window.adsbygoogle || []).push({ google_ad_client: “ca-pub-5707738102681835”, enable_page_level_ads: true }); –>Maryland and Missouri Have Legalized Recreational Cannabis

<!– Click –>

]]>
MariMed Opens its First Medical Cannabis Dispensary in Maryland, Will Host a Grand Opening Event with Local Officials https://mjshareholders.com/marimed-opens-its-first-medical-cannabis-dispensary-in-maryland-will-host-a-grand-opening-event-with-local-officials/ Wed, 05 Oct 2022 15:50:01 +0000 https://www.cannabisfn.com/?p=2964648

Ryan Allway

October 5th, 2022

News, Top News


Annapolis-based dispensary will feature full portfolio of MariMed products

NORWOOD, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) — MariMed, Inc (CSE: MRMD), (OTCQX: MRMD), (“MariMed” or the “Company”), a leading multi-state cannabis operator focused on improving lives every day, today announced the opening of its first dispensary in Maryland. Operated by the Company’s wholly owned subsidiary, Kind Therapeutics USA (“Kind”), the 5,000 square foot, Panacea Wellness-branded dispensary features MariMed’s portfolio of award-winning brands, including Nature’s Heritage craft flower and concentrates, Betty’s Eddies all-natural fruit chews, and Bubby’s Baked soft baked goods. The dispensary is located at 2061 Generals Highway in Annapolis. More information about the dispensary is available at www.panaceawellness.com.

A grand opening celebration for medical patients and local officials will be held at the dispensary on Tuesday, October 18, 2022. The event will kick off at 9:30 a.m. ET with a ribbon-cutting ceremony featuring remarks from Maryland State Senator Sarah Elfreth (D-Anne Arundel County), Maryland State Senator Brian Feldman (D-Montgomery County), Anne Arundel County Executive Steuart Pittman (D), Annapolis Mayor Gavin Buckley (D), MariMed President Jon Levine, and the Company’s Maryland General Manager Jeff Jones.

“We are proud to serve patients in the Annapolis region with our premium product offerings delivered by our highly trained team,” said MariMed President Jon Levine. “The recent expansion of our state-of-the-art production kitchen in Hagerstown enables us to offer our full portfolio of quality products at a time when the state’s medical cannabis patients are looking for new and innovative offerings. We are particularly optimistic about the future of our business in Maryland as an adult-use referendum is expected to pass in November 2022.”

In addition to Panacea Wellness Annapolis, under state regulations MariMed can own up to three additional dispensaries in Maryland. MariMed also currently owns or manages dispensaries in Illinois, Massachusetts, and Delaware, with additional sites under development in Illinois, Massachusetts, and Ohio. The Company continues to review accretive acquisitions in other legal cannabis states.

With the opening of the dispensary in Annapolis, MariMed is a fully vertical cannabis operator in the state of Maryland. The Company operates a 90,000 square foot cultivation and production facility in Hagerstown. MariMed’s branded cannabis products are distributed to virtually all the approximately 100 dispensaries in the Maryland medical cannabis program.

According to the Maryland Medical Cannabis Commission, the state generated more than $550 million in medical cannabis sales in 2021, with nearly 150,000 registered medical cannabis patients. According to Cowen Research, with a population of 6.2 million, Maryland’s medical cannabis program boasts some of the highest rates of registered medical consumers, and incidence usage and spending, on a per capita basis, among all legal medical cannabis programs in the United States.

For more information about MariMed, visit www.marimedinc.com.

About MariMed
MariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units. Proprietary formulations created by the Company’s technicians are embedded in its top-selling and award-winning products and brands, including Betty’s Eddies, Nature’s Heritage, Bubby’s Baked, K Fusion, Kalm Fusion, and Vibations: High + Energy. For additional information, visit www.marimedinc.com.

For Questions Contact

Investor Relations
Steve West
Vice President, Investor Relations
Email: [email protected]
Phone: (781) 277-0007

Company Contact:
Howard Schacter
Chief Communications Officer
Email: [email protected]
Phone: (781) 277-0007

Media Contact:
Trailblaze PR
Email: [email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
MariMed Receives Maryland State Approval for Transfer of Ownership of Kind Therapeutics USA https://mjshareholders.com/marimed-receives-maryland-state-approval-for-transfer-of-ownership-of-kind-therapeutics-usa/ Thu, 14 Apr 2022 14:23:29 +0000 https://www.cannabisfn.com/?p=2943921

Ryan Allway

April 14th, 2022

News, Top News


NORWOOD, Mass., April 14, 2022 (GLOBE NEWSWIRE) — MariMed Inc. (OTCQX: MRMD) (“MariMed” or the “Company”), a leading multi-state cannabis operator focused on improving lives every day, today announced that the Maryland Medical Cannabis Commission (MMCC) has approved the transfer of 100% of the ownership of Kind Therapeutics U.S.A., LLC (“Kind”), a leading vertically integrated cannabis business to MariMed Inc.

The approval was granted during the MMCC’s Full Commission Meeting on Wednesday, April 13, 2022. The parties will now move forward to complete the closing of the transactions previously announced. Upon closing, Kind will become a wholly owned subsidiary of MariMed and its financials will be consolidated with MariMed’s in the Company’s public filings.

Kind operates under its cannabis cultivation and production licenses in its Hagerstown, MD manufacturing plant. It is completing development of a dispensary in Anne Arundel County under its provisional dispensary license. Kind’s cannabis products, including MariMed brands, are distributed to the approximately 100 medical dispensaries in the Maryland medical cannabis program. Maryland’s medical cannabis program has more than 139,000 registered patients and, according to the MMCC, the state receives more than 200 applications for medical cannabis cards every day. Maryland’s medical cannabis program generated more than $500 million in sales in 2021. According to Cowen Research, with a population of 6.2 million, Maryland’s medical cannabis program boasts some of the highest rates of registered medical consumers, incidence usage and spending, on a per capita basis, among all legal medical cannabis programs in the United States. The state legislature recently approved a November 2022 ballot referendum for voters to approve an adult use cannabis program.

About MariMed
MariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units. Proprietary formulations created by the Company’s technicians are embedded in its top-selling and award-winning products and brands, including Betty’s Eddies, Nature’s Heritage, Bubby’s Baked, K Fusion, Kalm Fusion, and Vibations: High + Energy. For additional information, visit www.marimedinc.com.

Investor Relations Contact:
Steve West
Vice President, Investor Relations
Email: [email protected]

Media Contact:
Trailblaze PR
Email: [email protected]

Company Contact:
Howard Schacter
Chief Communications Officer
Email: [email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Legislators In Maryland Want To Correct The States Cannabis Legislation In 2022 https://mjshareholders.com/legislators-in-maryland-want-to-correct-the-states-cannabis-legislation-in-2022/ Mon, 27 Dec 2021 20:45:00 +0000 https://marijuanastocks.com/?p=51027 Maryland Legislators File A Referendum For 2022 Session

The post Legislators In Maryland Want To Correct The States Cannabis Legislation In 2022 appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

]]>

<!– (adsbygoogle = window.adsbygoogle || []).push({ google_ad_client: “ca-pub-5707738102681835”, enable_page_level_ads: true }); –>Legislators In Maryland Want To Correct The States Cannabis Legislation In 2022

<!– Click –>

]]>